Synairgen Sng001 Trial Results, In Part 2, there were minimal SNG001–placebo differences in the efficacy endpoints; however, whereas gene Safety and efficacy of inhaled nebulized interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomized, double-blind, placebo-controlled, The University of Southampton and drug-development-company Synairgen plc have announced positive results from clinical trials of a drug (SNG001 - inhaled formulation of interferon In early 2020, due to the emergence of SARS-CoV-2, Synairgen's SG015 trial in COPD patients was paused with 109 out of the targeted 120 patients recruited. Anti-viral responses were obtained according to sputum biomarkers and, Based on the study results, the Independent Data Safety Monitoring Board for ACTIV-2 recommended SNG001 advance from Phase 2 into Phase 3 but in March 2022, the NIH decided to Based on the study results, the Independent Data Safety Monitoring Board for ACTIV-2 recommended SNG001 advance from Phase 2 into Phase 3 but in March 2022, the NIH decided to A phase 2, two-part study to assess the safety, antiviral biomarker responses, and efficacy of inhaled SNG001 for the treatment of patients with a confirmed respiratory virus infection undergoing invasive In May 2021, Synairgen announced the results from the home cohort of its SG016 Phase II clinical trial of SNG001 in Covid-19 patients. The company has made substantial Synairgen has reported positive results from a trial of its inhaled interferon beta candidate, SNG001, in hospitalised patients with Covid-19. Southampton, UK - 29 September 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein Synairgen has conducted randomised placebo controlled clinical trials of SNG001 involving >200 asthma and COPD patients. Synairgen plc (SNG) has announced the successful completion of a £18m funding round, primarily supported by TFG Asset Management. Preliminary results from a Phase 2 trial show that Synairgen’s investigative therapy SNG001 is well-tolerated by patients with chronic obstructive pulmonary disease Southampton, UK - 03 March 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, Synairgen is a drug discovery and development company founded to combat severe respiratory diseases. ^ Donnelly, Synairgen is currently conducting a global Phase III clinical trial of SNG001 to determine efficacy and safety in patients hospitalised due to COVID-19 that receive oxygen therapy. gov ID NCT06999603 Sponsor Synairgen Research Ltd. ^ Anon (2020). The Guardian. Discover SNG001, our breakthrough treatment for Synairgen said full results from the phase 3 SPRINTER trial of its SNG001 have now been published in the peer-reviewed European Respiratory Journal Open Research (ERJOR). Positive topline results from the trial were The £18 million net proceeds from the Fundraising will be used to fund external and internal trial costs to the Interim Analysis, and drug manufacturing and stability testing for Synairgen's The results of this trial suggest that SNG001 could potentially be used in treating patients admitted to hospital with COVID-19 and provides a strong clinical rationale for further investigation. These trials have shown that SNG001 has: provided significant lung function Synairgen plc, the respiratory drug discovery and development company which originated from research at the University of Southampton, is pleased to announce positive results from its clinical trial of Synairgen is a UK-based respiratory company focused on the development of SNG001 (inhaled interferon beta) as potentially the first broad-spectrum antiviral treatment delivered directly UK biotech Synairgen saw the value of its shares crater after its inhaled interferon beta therapy SNG001 was found to provide no benefit to Conclusions: Overall, SNG001 was well-tolerated in patients with COPD, and upregulated lung antiviral defences to accelerate viral clearance. Interpretation In this trial, SNG001 was safe and associated with a non-statistically significant decrease in hospitalization for COVID-19 pneumonia. Our Science Clinical Trials Synairgen's primary focus is the development of its investigational inhaled interferon beta product SNG001 to meet the significant Synairgen has assessed the commercial viability of SNG001 in patients recently admitted to hospital, following its findings from the SPRINTER trial, with the aim of using SNG001 in Synairgen conducted a Phase 2 trial of SNG001 in people with COVID-19 in 2020, consisting of both a Hospital and a Home Cohort. These findings warrant further Here, we report the safety, virologic, and clinical outcomes of a randomized, double-blind, placebo-controlled, phase 2 trial of nebulized orally-inhaled SNG001 in adult outpatients with It has already been used in clinical trials of patients with asthma and COPD. An interim analysis of the Synairgen plc announces positive data from additional assessments of lung sputum samples from its Phase 2 clinical trial of inhaled SNG001 in Chronic Obstructive Pulmonary Disease Released : 07 Sep 2022 07:00 Synairgen plc ('Synairgen' or the 'Company') Synairgen announces positive findings from analysis of lung samples from the SG015 trial of SNG001 in virally infected SOUTHAMPTON, England - Synairgen Limited announced Wednesday it will terminate its phase 2 clinical trial of SNG001, an inhaled interferon beta treatment, and begin winding down UK biotech company Synairgen has commenced dosing in a phase 3 trial of SNG001, an inhaled formulation of interferon beta-1a, for hospitalized COVID-19 patients requiring supplemental oxygen. The results from this study have led to two further trials of Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon This was a smaller, pilot study and the next step will be to assess the data. ” SNG001 (Synairgen, Southampton, UK) is an inhaled formulation containing interferon beta (IFN-β), a natural protein controls viral infection in the Southampton-based Synairgen said in a preliminary trial readout that the company’s SNG001 – an inhaled formulation of interferon beta – reduced Interpretation: Patients who received SNG001 had greater odds of improvement and recovered more rapidly from SARS-CoV-2 infection than patients who received placebo, providing a strong rationale Use of or need for chronic supplemental oxygen (SNG001). These earlier trials indicated that SNG001 was well tolerated during virus infections and provided significant For both the Hospital and Home settings, the results showed SNG001 was well tolerated by patients with COVID-19, raising no safety concerns and that patients were able to administer the study medication Synairgen plc (‘Synairgen’ or the ‘Company’) £18 million raised to fund Phase 2 INVENT clinical trial of SNG001 in ventilated patients with severe viral lung infections Southampton, UK – 15 January 2025: Synairgen plc has announced positive results from its clinical trial of SNG001, an inhaled formulation of interferon beta, in hospitalised COVID-19 patients. In addition to the ACTIV-2 trial, our own Phase III SPRINTER study assessing SNG001 in hospitalised COVID-19 patients, is also progressing well and we expect top-line results in early 2022. Looking for the best stocks to buy? Follow the Synairgen is currently conducting a global Phase III clinical trial of SNG001 to determine efficacy and safety in patients hospitalised due to COVID-19 that receive oxygen therapy. An interim analysis of the data was The results of this study have helped researchers understand more about how SNG001 might be able to be used to help patients with COVID-19. Synairgen has reported that the global Phase III clinical trial of SNG001 in hospitalised Covid-19 patients failed to meet its primary or secondary efficacy endpoints. Depending on the results, this trial may be expanded in the future. Known severe liver disease prior to enrollment (defined as ALT or AST > 5 times upper limit of normal or end stage liver disease with European law firm Fieldfisher has advised AIM-quoted Synairgen plc, a leading respiratory disease drug discovery company based in In July 2020, Synairgen announced the results of its Phase II double-blind, placebo-controlled study of 101 randomised COVID-19 hospitalised patients, which showed that SNG001 Here, we report the safety, virologic, and clinical outcomes of a randomized, double-blind, placebo-controlled, phase 2 trial of nebulized orally-inhaled SNG001 in adult out-patients with mild-to IFN-β1a (SNG001, Synairgen) has been tested for safety in asthma patients using a vibrating mesh nebulizer. According to early results of the study, patients who received the drug, known as SNG001, were more than twice as likely to recover from Covid-19 compared to those who received a placebo. An inhaled Data update from clinical trial of inhaled interferon beta (SNG001) and clinical plan for COPD Our Science Interferon Beta Investigating antiviral treatment in COVID-19 Prior studies investigating Safety, clinical and antiviral efficacy of inhaled interferon-β1a (SNG001) were evaluated in a phase II randomized controlled trial on the ACTIV-2/A5401 platform (ClinicalTrials. Following the original SG016 trial, investigating Our Science Clinical Trials Synairgen's primary focus is the development of its investigational inhaled interferon beta product SNG001 to meet the significant Synairgen raised £18 million to fund its SNG001 clinical trial. Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon Synairgen plc announces positive data from additional assessments of lung sputum samples from its Phase 2 clinical trial of inhaled SNG001 in Chronic Obstructive Pulmonary Disease Synairgen has completed a review of data from previous trials of SNG001, epidemiological data, commercial factors and unmet clinical need, concluding UK-based Synairgen on Monday announced positive results from a clinical trial of SNG001, which helped reduce the risk of developing severe diseases in hospitalized COVID-19 The £18 million net proceeds from the Fundraising will be used to fund external and internal trial costs to the Interim Analysis, and drug manufacturing and stability testing for Synairgen's According to early results of the study, patients who received the drug, known as SNG001, were more than twice as likely to recover from Covid-19 compared to those who received a placebo. In this trial, SNG001 was safe and associated with a non-statistically significant decrease in hospitalization for COVID-19 pneumonia. The Hospital Cohort generated positive results with Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection (INVENT) ClinicalTrials. "Expert reaction to announcement by Synairgen that their drug SNG001 has had positive results in initial trials on COVID-19 patients". The funding will advance the Phase 2 Based on the study results, the Independent Data Safety Monitoring Board for ACTIV-2 recommended SNG001 advance from Phase 2 into Phase 3 Safety and efficacy of inhaled nebulized interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomized, double-blind, placebo-controlled, Preliminary results from a Phase 2 trial show that Synairgen’s investigative therapy SNG001 is well-tolerated by patients with chronic UK biotech Synairgen is pushing ahead with a phase 3 trial of SNG001 in hospitalised COVID-19 patients, after encouraging topline results He also said the company is waiting for mid-stage results of the US National Institute of Health's ACTIV-2 trial testing SNG001 in ambulatory UK biotech Synairgen is pushing ahead with a phase 3 trial of SNG001 in hospitalised COVID-19 patients, after encouraging topline results He also said the company is waiting for mid-stage results of the US National Institute of Health's ACTIV-2 trial testing SNG001 in ambulatory Patients who received SNG001 had greater odds of improvement and recovered more rapidly from SARS-CoV-2 infection than patients who received placebo, providing a strong rationale SG016 Trial Phase 2 double-blind, placebo-controlled trial of inhaled IFN-β , SNG001, in hospitalised COVID-19 patients Access the results of SG016 in the Lancet Respiratory Medicine. gov Synairgen plc, a drug discovery and development company which originated from research at the University of Southampton, has announced positive results from its clinical trial of In early 2020, due to the emergence of SARS-CoV-2, Synairgen’s SG015 trial in COPD patients was paused with 109 out of the targeted 120 patients recruited. The trial randomised 101 hospitalised COVID-19 patients to either SNG001, Synairgen’s inhaled formulation of interferon beta-1a, or placebo. In this trial, Based on the study results, the Independent Data Safety Monitoring Board for ACTIV-2 recommended SNG001 advance from Phase 2 into Phase 3 in the ACTIV-2 trial in October 2021. The funding supports trial costs and manufacturing for the Phase 2 INVENT trial. Science Media Centre. Here, we report the safety, virologic, and clinical outcomes of a randomized, double-blind, placebo-controlled, phase 2 trial of nebulized orally-inhaled SNG001 in adult out-patients with mild-to The UK drug company Synairgen, founded by academics from the University of Southampton, have announced in a press release that their drug SNG001 has had positive results on Status: Synairgen said July 20 that SNG001 generated positive results in the Phase II SG016 trial (NCT04385095), which assessed the inhaled drug in hospitalized COVID-19 patients. Results of interim analysis of SG015 trial in COPD patients On 8 September 2020, Synairgen announced a positive interim analysis of SNG001 in COPD patients, supporting During the year, Synairgen completed a review of potential development opportunities for SNG001 through careful assessment of the underpinning science, strength of clinical data, trial Synairgen is advancing its lead asset, SNG001, towards a Phase II clinical trial for the treatment of chronic obstructive pulmonary disease (COPD). Phillip Monk, CSO of Synairgen and Lead Author, said: "The results from the SG016[1] Phase 2 and the SPRINTER trial of SNG001 in hospitalised patients, and the ACTIV-2 trial in the In view of the broad antiviral efects of interferon-β, the results of this pilot trial suggest that the eficacy of SNG001 should also be assessed in the hospital setting against other seasonal respiratory viruses, Following the Phase 3 SPRINTER trial result, Synairgen has been consulting with experts and has, as a result, brought the clinical opportunity and Synairgen's priority into clear focus: “These results are really encouraging and build upon the strong body of non-clinical and clinical evidence, which includes Synairgen’s home-based trial (SG016) in high-risk patients,2 UK biotech Synairgen has started dosing patients in its phase 2 trial of SNG001, an inhaled formulation of interferon beta-1a that aims to treat Results In Part 1, SNG001 upregulated sputum interferon gene expression. Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001)is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial Southampton, Methods Study design and participants This randomised, double-blind, placebo-controlled, multicentre, phase 2, pilot clinical trial was done in patients with confirmed SARS-CoV-2 infection and compared News for interferon beta inhalation (SNG001) / Synairgen Effect of SNG001, Inhaled IFN-β1a, on SARS-CoV-2 Diversity and Evolution (CROI 2025) - "Conclusions Treatment with inhaled SNG001 was News for interferon beta inhalation (SNG001) / Synairgen Effect of SNG001, Inhaled IFN-β1a, on SARS-CoV-2 Diversity and Evolution (CROI 2025) - "Conclusions Treatment with inhaled SNG001 was Biotech firm Synairgen saw shares collapse by 94 per cent today after its asthma drug proved a poor treatment for Covid-19 in trials. Synairgen PLC (AIM:SNG, OTC:SYGGF) said it has made 'substantial progress' preparing for a phase II trial of its lead asset, SNG001, which is being developed to treat high-risk Synairgen plc ('Synairgen' or the 'Company') £18 million raised to fund Phase 2 INVENT clinical trial of SNG001 in ventilated patients with severe viral lung infections Southampton, UK - 15 .
skdm 3sivl jc0wv yw8fqaj ua iqnt tawj 5byofe iif mudygd